Pros | - | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 2 Years | 12 Years | ||
Fund Size | 409 Cr | 8737 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.8% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 24 | 41 | ||
Top 5 Holdings | Aster DM Healthcare Ltd Ordinary Shares (10.01%) RPG Life Sciences Ltd (8.83%) Zydus Wellness Ltd (6.36%) Sequent Scientific Ltd (6.21%) Alivus Life Sciences Ltd (6.21%) | Sun Pharmaceuticals Industries Ltd (12.22%) Divi's Laboratories Ltd (7.55%) Lupin Ltd (5.93%) Cipla Ltd (5.69%) Dr Reddy's Laboratories Ltd (5.69%) | ||
No of Sectors | 4 | 1 | ||
Top 3 Sectors | Health (80.53%) Consumer Defensive (7.61%) Financial Services (6.57%) | Health (100%) | ||
Equity % | 99.31% | 99.45% | ||
Debt % | - | - | ||
P/E | 34.58 | 37.97 | ||
P/B | 4.64 | 6.05 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -3.21% | -3.87% | ||
3-Month Return | -3.53% | 1.23% | ||
6-Month Return | 12.82% | 13.03% | ||
1-Year Return | -12.29% | 0.02% | ||
3-Year Return | - | 23.96% | ||
5-Year Return | - | 19.11% |
Sharpe | - | 1.2 | ||
Alpha | - | 1 | ||
Beta | - | 0.9 | ||
Standard Deviation | - | 14.63 | ||
Information Ratio | - | -0.22 |
Description | Quant Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sanjeev Sharma,Sandeep Tandon,Ayusha Kumbhat,Varun Pattani,Yug Tibrewal,Ankit A. Pande,Sameer Kate | Sailesh Raj Bhan,Kinjal Desai |